<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713670</url>
  </required_header>
  <id_info>
    <org_study_id>202004063MINA</org_study_id>
    <nct_id>NCT04713670</nct_id>
  </id_info>
  <brief_title>Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection</brief_title>
  <official_title>Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection - a Multicenter, Open Labelled, Randomized Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Bismuth quadruple therapy is currently the recommended first-line regimen for&#xD;
      Helicobacter pylori (H. pylori) infection in regions with high clarithromycin resistance.&#xD;
      Recent randomized trials showed that 7-day vonoprazan-based triple therapy is superior to&#xD;
      7-day lansoprazole-based triple therapy in Japanese. A recent trial further showed that 7-day&#xD;
      vonoprazan-based high dose amoxicillin dual therapy was non-inferior to 7-day&#xD;
      vonoprazan-based triple therapy in Japanese. However, whether vonoprazan based dual, triple,&#xD;
      and quadruple therapies are superior or non-inferior to lansoprazole based triple or&#xD;
      quadruple therapy remains unknown.&#xD;
&#xD;
      Objective: The investigators aimed to compare the efficacy and safety of 14-day&#xD;
      vonoprazan-based dual therapy, triple therapy, bismuth quadruple therapy, reverse hybrid&#xD;
      therapy, and lansoprazole-based bismuth quadruple therapy and triple therapy in the&#xD;
      first-line treatment of H. pylori infection in this pilot study.&#xD;
&#xD;
      Methods: Using a block randomization with a block size of 16 in a 1:1 ratio, 320 eligible&#xD;
      adult subjects aged 20 years or greater with at least two positive tests for H. pylori&#xD;
      infection will be randomized to receive one of the following regimens: (A) vonoprazan-based&#xD;
      triple therapy for 14 days (T-V14): vonoprazan 20mg twice daily, clarithromycin-XL 500mg&#xD;
      twice daily, amoxicillin 1000mg twice daily for 14 days ; or (B) vonoprazan-based triple&#xD;
      therapy for 7 days (T-V7): vonoprazan 20mg twice daily, clarithromycin-XL 500mg twice daily,&#xD;
      amoxicillin 1000mg twice daily for 7 days ; or (C): vonoprazan-based dual therapy for 14 days&#xD;
      (D-V14): vonoprazan 20mg twice daily, amoxicillin 750mg every 8 hour for 14 days; (D):&#xD;
      vonoprazan-based high dose dual therapy for 14 days (HD-V14): vonoprazan 20mg twice daily,&#xD;
      amoxicillin 750mg four times a day for 14 days; or (E) vonoprazan-based bismuth quadruple&#xD;
      therapy for 14 days (BQ-V14) vonoprazan 20mg twice daily, bismuth tripotassium dicitrate 300&#xD;
      mg three times a day, tetracycline 500mg three times a day, and metronidazole 500mg three&#xD;
      times a day for 14 days; or (F) vonoprazan-based reverse hybrid therapy for 14 days (RH-V14):&#xD;
      vonoprazan 20mg twice daily, and amoxicillin 1000mg twice daily for 14 days, plus&#xD;
      clarithromycin-XL 500mg twice daily and metronidazole 500mg twice daily for the first 7 days&#xD;
      ; or (G) lansoprazole-based bismuth quadruple therapy for 14 days (BQ-L14) lansoprazole 30mg&#xD;
      twice daily, bismuth tripotassium dicitrate 300 mg three times a day, tetracycline 500mg&#xD;
      three times a day, and metronidazole 500mg three times a day for 14 days; or (H)&#xD;
      lansoprazole-based triple therapy for 14 days (T-L14): lansoprazole 30mg twice daily,&#xD;
      clarithromycin-XL 500mg twice daily, amoxicillin 1000mg twice daily for 14 days. Subjects who&#xD;
      fail after first-line therapy will be randomized to receive either vonoprazan-based&#xD;
      levofloxacin triple therapy (LT-V14) containing vonoprazan 20mg twice daily, levofloxacin&#xD;
      250mg twice daily, and amoxicillin 1000mg twice daily for 14 days or vonoprazan-based&#xD;
      levofloxacin reverse hybrid therapy (LRH-V14) containing vonoprazan 20mg twice daily, and&#xD;
      amoxicillin 1000mg twice daily for 14 days, plus levofloxacin 250mg twice daily and&#xD;
      metronidazole 500mg twice daily for the first 7 days. The minimum inhibitory concentrations&#xD;
      will be determined by agar dilution test. 23S ribosomal RNA and gyrase A mutations will be&#xD;
      determined by PCR methods followed by direct sequencing in a subgroup of patients. The TWB2.0&#xD;
      SNP array will be used for genotyping of genome wide single nucleotide polymorphism.&#xD;
&#xD;
      Outcome analysis: The primary outcome is the eradication rate in the first-line treatment.&#xD;
      The secondary outcomes are the compliance, frequency of adverse events, the overall&#xD;
      eradication rate after two treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Bismuth quadruple therapy is currently the recommended first-line regimen for&#xD;
      Helicobacter pylori (H. pylori) infection in regions with high clarithromycin resistance.&#xD;
      Recent randomized trials showed that 7-day vonoprazan-based triple therapy is superior to&#xD;
      7-day lansoprazole-based triple therapy in Japanese. A recent trial further showed that 7-day&#xD;
      vonoprazan-based high dose amoxicillin dual therapy was non-inferior to 7-day&#xD;
      vonoprazan-based triple therapy in Japanese. However, whether vonoprazan based dual, triple,&#xD;
      and quadruple therapies are superior or non-inferior to lansoprazole based triple or&#xD;
      quadruple therapy remains unknown.&#xD;
&#xD;
      Objective: The investigators aimed to compare the efficacy and safety of 14-day&#xD;
      vonoprazan-based dual therapy, triple therapy, bismuth quadruple therapy, reverse hybrid&#xD;
      therapy, and lansoprazole-based bismuth quadruple therapy and triple therapy in the&#xD;
      first-line treatment of H. pylori infection in this pilot study. The long-term changes in gut&#xD;
      microbiota, antibiotic resistance, trimethylamine-N-oxide (TMAO) levels, and metabolic&#xD;
      parameters after eradication therapies will also be investigated.&#xD;
&#xD;
      Methods: Using a block randomization with a block size of 16 in a 1:1 ratio, 320 eligible&#xD;
      adult subjects aged 20 years or greater with at least two positive tests for H. pylori&#xD;
      infection will be randomized to receive one of the following regimens: (A) vonoprazan-based&#xD;
      triple therapy for 14 days (T-V14): vonoprazan 20mg twice daily, clarithromycin-XL 500mg&#xD;
      twice daily, amoxicillin 1000mg twice daily for 14 days ; or (B) vonoprazan-based triple&#xD;
      therapy for 7 days (T-V7): vonoprazan 20mg twice daily, clarithromycin-XL 500mg twice daily,&#xD;
      amoxicillin 1000mg twice daily for 7 days ; or (C): vonoprazan-based dual therapy for 14 days&#xD;
      (D-V14): vonoprazan 20mg twice daily, amoxicillin 750mg every 8 hour for 14 days; (D):&#xD;
      vonoprazan-based high dose dual therapy for 14 days (HD-V14): vonoprazan 20mg twice daily,&#xD;
      amoxicillin 750mg four times a day for 14 days; or (E) vonoprazan-based bismuth quadruple&#xD;
      therapy for 14 days (BQ-V14) vonoprazan 20mg twice daily, bismuth tripotassium dicitrate 300&#xD;
      mg three times a day, tetracycline 500mg three times a day, and metronidazole 500mg three&#xD;
      times a day for 14 days; or (F) vonoprazan-based reverse hybrid therapy for 14 days (RH-V14):&#xD;
      vonoprazan 20mg twice daily, and amoxicillin 1000mg twice daily for 14 days, plus&#xD;
      clarithromycin-XL 500mg twice daily and metronidazole 500mg twice daily for the first 7 days&#xD;
      ; or (G) lansoprazole-based bismuth quadruple therapy for 14 days (BQ-L14) lansoprazole 30mg&#xD;
      twice daily, bismuth tripotassium dicitrate 300 mg three times a day, tetracycline 500mg&#xD;
      three times a day, and metronidazole 500mg three times a day for 14 days; or (H)&#xD;
      lansoprazole-based triple therapy for 14 days (T-L14): lansoprazole 30mg twice daily,&#xD;
      clarithromycin-XL 500mg twice daily, amoxicillin 1000mg twice daily for 14 days. Subjects who&#xD;
      fail after first-line therapy will be randomized to receive either vonoprazan-based&#xD;
      levofloxacin triple therapy (LT-V14) containing vonoprazan 20mg twice daily, levofloxacin&#xD;
      250mg twice daily, and amoxicillin 1000mg twice daily for 14 days or vonoprazan-based&#xD;
      levofloxacin reverse hybrid therapy (LRH-V14) containing vonoprazan 20mg twice daily, and&#xD;
      amoxicillin 1000mg twice daily for 14 days, plus levofloxacin 250mg twice daily and&#xD;
      metronidazole 500mg twice daily for the first 7 days. The minimum inhibitory concentrations&#xD;
      will be determined by agar dilution test. 23S ribosomal RNA and gyrase A mutations will be&#xD;
      determined by PCR methods followed by direct sequencing in a subgroup of patients. The TWB2.0&#xD;
      SNP array will be used for genotyping of genome wide single nucleotide polymorphism. Fecal&#xD;
      and oral samples will be collected for 16S and shot-gun sequencing at baseline, week 2, week&#xD;
      8, year 1, and year 2. Metabolic parameters will be measured at baseline, week 8, year 1, and&#xD;
      year 2. Modified carnitine challenge test (mCCT) will be done to assess the production of&#xD;
      urine TMAO at baseline, week 2, week 8, year 1, and year 2 in a subgroup of study subjects.&#xD;
&#xD;
      Outcome analysis: The primary outcome is the eradication rate in the first-line treatment.&#xD;
      The secondary outcomes are the compliance, frequency of adverse events, the overall&#xD;
      eradication rate after two treatments. The long-term outcomes are the cumulative eradication&#xD;
      rate, the changes of gut microbiota, antibiotic resistance, TMAO production, and metabolic&#xD;
      parameters at year 1 and year 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the eradication rate in the first-line treatment.</measure>
    <time_frame>Up to 8-12 weeks</time_frame>
    <description>At least 6 weeks after the end of treatment, the carbon 13-breath test will be used to evaluate whether the eradication is successful. The eradication rate in each group will be presented as &quot;%&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcomes are the compliance and frequency of adverse events.</measure>
    <time_frame>Up to 8-12 weeks</time_frame>
    <description>After eradication treatment, participants will go back to the outpatients clinics to evaluate whether they take all of or &gt; 80% drugs. The investigators will also record any side effect associated with treatment, such as skin rash, dizziness, headache, taste distortion, and etc. The severity grading include &quot;none&quot;, &quot;mild&quot;, &quot;moderate&quot;, &quot;severe&quot; and &quot;life-threatening&quot;.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>H. Pylori Infection</condition>
  <arm_group>
    <arm_group_label>(A) T-V14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>(B) T-V7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>(C) D-V14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>(D) HD-V14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>(E) BQ-V14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>(F) RH-V14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>(G) BQ-L14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>(H) T-L14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(A) T-V14</intervention_name>
    <description>vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)</description>
    <arm_group_label>(A) T-V14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(B) T-V7</intervention_name>
    <description>vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)</description>
    <arm_group_label>(B) T-V7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(C) D-V14</intervention_name>
    <description>vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)</description>
    <arm_group_label>(C) D-V14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(D) HD-V14</intervention_name>
    <description>vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)</description>
    <arm_group_label>(D) HD-V14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(E) BQ-V14</intervention_name>
    <description>vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)</description>
    <arm_group_label>(E) BQ-V14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(F) RH-V14</intervention_name>
    <description>vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)</description>
    <arm_group_label>(F) RH-V14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(G) BQ-L14</intervention_name>
    <description>lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)</description>
    <arm_group_label>(G) BQ-L14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(H) T-L14</intervention_name>
    <description>lansoprazole(takepron)-based triple therapy for 14 days (T-L14)</description>
    <arm_group_label>(H) T-L14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with naive H. pylori infection&#xD;
&#xD;
          2. Subjects with over 20 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Younger than 20 years old&#xD;
&#xD;
          2. Ever received H. eradication therapy&#xD;
&#xD;
          3. ever received total or subtotal gastrectomy in the past&#xD;
&#xD;
          4. Severe chronic disease, such as end stage renal disease, liver cirrhosis, incurable&#xD;
             malignant tumors&#xD;
&#xD;
          5. Women who are pregnant or breastfeeding&#xD;
&#xD;
          6. Those who are not suitable to receive study drugs: such as a history of allergies to&#xD;
             study drugs or serious side effects, etc.&#xD;
&#xD;
          7. Patients with chronic hepatitis (AST or ALT &gt;40 IU/L)&#xD;
&#xD;
          8. Subjects who cannot sign informed consent by themselves&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mei-Jyh Chen, MD</last_name>
    <phone>88623123456</phone>
    <phone_ext>66280</phone_ext>
    <email>migichen@ntuh.gov.tw</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 10, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H.pylori</keyword>
  <keyword>vonoprazan</keyword>
  <keyword>lansoprazole</keyword>
  <keyword>triple therapy</keyword>
  <keyword>high dose dual therapy</keyword>
  <keyword>bismuth quadruple</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

